Tcr2 Therapeutics Inc (TCRR)

NASDAQ
7.88
-0.01(-0.13%)
After Hours
7.83
-0.05(-0.63%)
- Real-time Data
  • Volume:
    604,226
  • Bid/Ask:
    7.81/8.11
  • Day's Range:
    7.75 - 7.94

TCRR Overview

Prev. Close
7.89
Day's Range
7.75-7.94
Revenue
-
Open
7.94
52 wk Range
7.62-35.85
EPS
-2.33
Volume
604,226
Market Cap
301.37M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
648,146
P/E Ratio
-
Beta
-
1-Year Change
-60.14%
Shares Outstanding
38,196,290
Next Earnings Date
Nov 17, 2021
What is your sentiment on Tcr2 Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Tcr2 Therapeutics Inc News

Tcr2 Therapeutics Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuySellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryBuyBuyStrong SellStrong SellStrong Sell

Tcr2 Therapeutics Inc Company Profile

Tcr2 Therapeutics Inc Company Profile

Employees
151

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. The company’s lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma; and TC-110 a TRuC-T cell targeting CD19-positive B-Cell hematological malignancies, including adult acute lymphoblastic leukemia, DLBCL, follicular lymphoma, and other non-hodgkin lymphomas that is in phase I/II clinical trial. It is also developing TC-510 for, GPC3, IL-15, and Allogenic for solid tumors, as well as DC70 for solid tumors and hematological malignancies. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Read More
  • what happens here is it worths to entry in TCRR ?
    0
    • Seems quite silent here...
      0
      • 27 - is this a good price?
        1
        • any opinion Alexandr ?
          0
      • price target raised to $58 from $33 at Mizuho price target raised to $45 from $35 at Piper Sandler price target raised to $65 from $46 at BMO Capital price target raised to $37 from $32 at H.C. Wainwright
        0
        • the best paper ever)
          0
          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.